Medicare covers most FDA-approved multiple sclerosis (MS) drugs, but beneficiaries must navigate important limits such as prior authorizations and plan formularies. Recent updates could significantly change out-of-pocket costs and coverage options starting in 2026.
Understanding Medicare's coverage for multiple sclerosis drugs is crucial for beneficiaries navigating their treatment options. With the complexities of prior authorizations and varying plan formularies, many may find the rules stricter than expected, especially as upcoming changes promise to reshape costs and access to essential medications in the near future.
Key Takeaways
- Infusion DMTs like Ocrevus and Tysabri are covered under Medicare Part B.
- Oral and injectable DMTs such as Tecfidera and Gilenya fall under Part D coverage.
- Beneficiaries face a 20% coinsurance for Part B infusions after meeting the deductible.
- Out-of-pocket costs for Part D drugs are capped at $2,100 in 2026.
- Prior authorization and step therapy requirements can affect access to medications.
- A $2,000 out-of-pocket cap for Part D starts in 2025, with lower prices for select drugs in 2026.
Related questions people ask
- What is the best Medicare plan for multiple sclerosis?
- Does Medicare cover drugs for multiple sclerosis?
- Does Medicare cover Ocrevus?
- Is Kesimpta covered by Medicare?
- What multiple sclerosis drugs are covered by Medicare?
- What are the eligibility requirements for Medicare coverage of MS treatments?
- Are there any restrictions on Medicare coverage for multiple sclerosis medications?
- What alternatives are available if Medicare does not cover my MS medication?
Understanding Medicare Coverage for Multiple Sclerosis Drugs
Infusion and Oral Medications Covered
Medicare provides coverage for a range of disease-modifying therapies (DMTs) essential for managing multiple sclerosis. Infusion therapies, such as Ocrevus and Tysabri, are covered under Part B when administered in a medical setting, while oral and injectable medications like Tecfidera and Gilenya fall under Part D, which is managed through private plan administrators.
Part B and Part D Coverage Details
Part B specifically covers MS drug infusion therapies and certain injectable drugs when given in a hospital, infusion center, or neurologist's office. Meanwhile, Part D offers prescription drug coverage, but access to preferred MS drugs like Ocrevus and Ocrevus Zunovo can vary based on the chosen plan's formulary.
Financial Implications of Medicare Coverage for MS Drugs
Cost Structure for Infusions and Prescriptions
When it comes to costs, beneficiaries should be aware that Part B requires a 20% coinsurance after the deductible for infusion therapies. For Part D, costs can vary significantly based on the plan's formulary, but starting in 2025, there will be a $2,000 out-of-pocket cap, which is a significant relief considering that annual DMT prices can range from $60,000 to $90,000.
Cost-Sharing Variability
Cost-sharing for medications can differ based on whether prescriptions are filled at network or out-of-network pharmacies. Once beneficiaries reach the out-of-pocket cap, Medicare will cover the remaining drug costs, providing a crucial safety net for those facing high medication expenses.
Key Exceptions to Medicare Coverage for MS Drugs
Prior Authorization and Step Therapy Requirements
Beneficiaries should note that prior authorization is often required for coverage, based on medical history and recommendations from specialists. Additionally, step therapy may mandate that patients try less expensive drugs before gaining access to more costly options under Part D, which can complicate treatment plans.
Formulary Exceptions and Overrides
If a specific MS drug is not covered by a beneficiary's plan, they can request a formulary exception. Plans may waive coverage restrictions or quantity limits upon request, and emergency 31-day supply coverage is available while pursuing these exceptions, ensuring that patients do not face interruptions in their treatment.
Eligibility Criteria for Medicare Coverage of MS Drugs
Requirements for Coverage
To qualify for coverage, patients must have a confirmed diagnosis of multiple sclerosis and require FDA-approved DMTs prescribed by approved physicians. Documentation of medical necessity and prior authorization is essential, as is evidence of disease activity, which can include MRI results or documented relapses.
Enrollment and Premiums
Individuals must enroll in a Medicare Part D prescription drug plan to receive coverage for their medications. Beneficiaries are also responsible for meeting plan deductibles and paying monthly premiums, which can vary widely among different plans.
Upcoming Changes to Medicare Coverage for MS Drugs
Significant Updates for 2026
Starting in 2025, a $2,000 out-of-pocket cap for Part D will be implemented, which is expected to ease the financial burden on beneficiaries. Additionally, Medicare plans for 2026 will feature lower prices on ten drugs, potentially improving access to necessary treatments.
Changes to Enrollment Processes
Beneficiaries should also be aware that some changes to the enrollment processes for prescription payment plans will take effect in 2026, which may affect how they access their medications.
Practical Tips for Navigating Medicare Coverage for MS Drugs
Strategies for Beneficiaries
Beneficiaries are encouraged to check their plan's formulary for coverage of specific MS drugs to avoid unexpected costs. Preparing for potential prior authorization delays by submitting complete medical records can also streamline the process and ensure timely access to medications.
Advocacy and Communication
If a drug is not listed in the formulary, beneficiaries should contact their plan's customer care center for assistance. Requesting a list of covered alternative drugs and discussing options with their doctor can also help navigate coverage challenges effectively.
Understanding the Implications of Medicare Coverage for MS Drugs
Navigating Medicare coverage for multiple sclerosis drugs can be complex, but understanding the available options is essential for beneficiaries. With most FDA-approved MS drugs covered and upcoming changes promising to enhance affordability and access, individuals can feel more empowered in managing their treatment plans.
Page content independently curated and maintained by David W. Bynon, Medicare Technical Operator, using a standardized, data-driven methodology designed for accurate, non-commercial Medicare plan interpretation and resolution.